Baldo Brian A
Molecular Immunology Unit, Kolling Institute of Medical Research, Royal North Shore Hospital of Sydney, St Leonards, Australia.
Department of Medicine, University of Sydney, Sydney, NSW Australia.
Anesthesiol Perioper Sci. 2023;1(2):16. doi: 10.1007/s44254-023-00018-2. Epub 2023 Jun 14.
The list of drugs patients may be exposed to during the perioperative and postoperative periods is potentially extensive. It includes induction agents, neuromuscular blocking drugs (NMBDs), opioids, antibiotics, sugammadex, colloids, local anesthetics, polypeptides, antifibrinolytic agents, heparin and related anticoagulants, blue dyes, chlorhexidine, and a range of other agents depending on several factors related to individual patients' clinical condition and progress in the postoperative recovery period. To avoid poor or ultrarapid metabolizers to a particular drug (for example tramadol and codeine) or possible adverse drug reactions (ADRs), some drugs may need to be avoided during or after surgery. This will be the case for patients with a history of anaphylaxis or other adverse events/intolerances to a known drug. Other drugs may be ceased for a period before surgery, e.g., anticoagulants that increase the chance of bleeding; diuretics for patients with acute renal failure; antihypertensives relative to kidney injury after major vascular surgery; and serotonergic drugs that together with some opioids may rarely induce serotonin toxicity. Studies of germline variations shown by genotyping and phenotyping to identify a predisposition of genetic factors to ADRs offer an increasingly important approach to individualize drug therapy. Studies of associations of human leukocyte antigen (HLA) genes with some serious delayed immune-mediated reactions are ongoing and variations of drug-metabolizing cytochrome CYP450 enzymes, P-glycoprotein, and catechol--methyltransferase show promise for the assessment of ADRs and non-responses to drugs, particularly opioids and other analgesics. Surveys of ADRs from an increasing number of institutions often cover small numbers of patients, are retrospective in nature, fail to clearly identify culprit drugs, and do not adequately distinguish immune-mediated from non-immune-mediated anaphylactoid reactions. From the many surveys undertaken, the large list of agents identified during and after anesthesia and surgery are examined for their ADR involvement. Drugs are classified into those most often involved, (NMBD and antibiotics); drugs that are becoming more frequently implicated, namely antibiotics (particularly teicoplanin), and blue dyes; those becoming less frequently involved; and drugs more rarely involved in perioperative, and postoperative adverse reactions but still important and necessary to keep in mind for the occasional potential sensitive patient. Clinicians should be aware of the similarities between drug-induced true allergic type I IgE/FcεRI- and pseudoallergic MRGPRX2-mediated ADRs, the clinical features of each, and their distinguishing characteristics. Procedures for identifying MRGPRX2 agonists and diagnosing and distinguishing pseudoallergic from allergic reaction mechanisms are discussed.
患者在围手术期和术后可能接触到的药物清单可能非常广泛。这包括诱导剂、神经肌肉阻滞药物(NMBDs)、阿片类药物、抗生素、舒更葡糖、胶体、局部麻醉剂、多肽、抗纤维蛋白溶解剂、肝素及相关抗凝剂、蓝色染料、氯己定,以及一系列其他药物,这取决于与个体患者临床状况和术后恢复期进展相关的几个因素。为避免对特定药物(例如曲马多和可待因)代谢不良或超快代谢的患者,或可能发生的药物不良反应(ADR),手术期间或术后可能需要避免使用某些药物。有过敏反应或对已知药物有其他不良事件/不耐受史的患者就是这种情况。其他药物可能在手术前停用一段时间,例如增加出血风险的抗凝剂;急性肾衰竭患者使用的利尿剂;大血管手术后与肾损伤相关的抗高血压药;以及与某些阿片类药物一起使用时可能很少诱发5-羟色胺毒性的5-羟色胺能药物。通过基因分型和表型分析来识别遗传因素对药物不良反应易感性的种系变异研究,为个体化药物治疗提供了越来越重要的方法。关于人类白细胞抗原(HLA)基因与一些严重的迟发性免疫介导反应之间关联的研究正在进行中,药物代谢细胞色素CYP450酶、P-糖蛋白和儿茶酚-O-甲基转移酶的变异,在评估药物不良反应和对药物(特别是阿片类药物和其他镇痛药)无反应方面显示出前景。越来越多机构进行的药物不良反应调查通常涵盖的患者数量较少,本质上是回顾性的,未能明确识别罪魁祸首药物,也没有充分区分免疫介导的过敏样反应和非免疫介导的过敏样反应。从进行的众多调查中,对麻醉和手术期间及术后确定的大量药物清单进行了药物不良反应参与情况的检查。药物分为最常涉及的药物(NMBD和抗生素);越来越频繁涉及的药物,即抗生素(特别是替考拉宁)和蓝色染料;涉及频率降低的药物;以及在围手术期和术后不良反应中较少涉及但对于偶尔出现的潜在敏感患者仍很重要且需要牢记的药物。临床医生应了解药物诱导的真正I型IgE/FcεRI介导的过敏反应和假过敏MRGPRX2介导的药物不良反应之间的相似性、各自的临床特征及其区别特征。讨论了识别MRGPRX2激动剂以及诊断和区分假过敏与过敏反应机制的程序。